Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma

Background Chimeric antigen receptor (CAR) T-cell therapy depends on T cells that are genetically modified to recognize and attack cancer cells. Their effectiveness thus hinges on the functionality of a patient’s own T cells. Since CAR T-cell therapy is currently only approved for advanced cancers a...

Full description

Saved in:
Bibliographic Details
Main Authors: Annette Künkele, Andrea Stroux, Olaf Penack, Lars Bullinger, Benedikt Obermayer, Charlotte Junkuhn, Phillip Schiele, Anna Luzie Walter, Frederik Hamm, David Busch, Mareike Frick, Frederik Damm, Julia Polansky, Marco Frentsch, Il-Kang Na, Jonas Kath, Dimitrios L Wagner
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/4/e010709.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://jitc.bmj.com/content/13/4/e010709.full

Similar Items